VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

Combination of perifosine and temsirolimus shows promise against malignant glioma

Aeterna Zentaris Inc. today announced that perifosine, its oral AKT inhibitor, combined with temsirolimus ("TEM"), was well tolerated in an investigator driven Phase 1 clinical trial in recurrent or progressive malignant glioma ("MG").

20 Nov 2012

Bevacizumab ruled out for stage III colorectal cancer

Findings from the AVANT trial do not support the use of bevacizumab in patients receiving oxaliplatin-based chemotherapy for resected stage III or high-risk stage II colon carcinoma.

19 Nov 2012

Positive results from Genentech Avastin plus temozolomide Phase III study on glioblastoma

Genentech, a member of the Roche Group, today announced results from the positive Phase III AVAglio study. The study showed Avastin (bevacizumab) in combination with radiation and temozolomide chemotherapy reduced the risk of cancer worsening or death (progression-free survival; PFS) by 36 percent compared to radiation and temozolomide chemotherapy plus placebo>th Annual Meeting of the Society for Neuro-Oncology in Washington, D.C.

19 Nov 2012

Study: Regular exercise before, during pregnancy could have beneficial effects for women

Contrary to popular thought, regular exercise before and during pregnancy could have beneficial effects for women that develop high blood pressure during gestation, human physiology professor Jeff Gilbert said, summarizing a new study by his research team that appears in the December issue of Hypertension, a journal of the American Heart Association.

16 Nov 2012

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.

7 Nov 2012

Adding angiogenesis inhibitor to anti-HER2 drugs extends survival in mice with breast cancer

Adding an angiogenesis inhibitor to treatment with a HER2-inhibiting drug could improve outcomes for patients with HER2-positive breast cancer who develop brain metastases. In their report published online in PNAS Plus, Massachusetts General Hospital (MGH) investigators report the first preclinical study combining antiangiogenic and anti-HER2 drugs in an animal model of brain metastatic breast cancer.

3 Nov 2012

Targeted deletion of major VEGF gene in mice induces vision loss

Millions of people with "wet" macular degeneration are prescribed a class of medication known as anti-VEGF drugs. But now scientists at The Scripps Research Institute (TSRI) have found that a drastic reduction of VEGF activity may do more harm than good.

26 Oct 2012

Ophthotech announces data from Fovista Phase 2b trial on wet AMD

Ophthotech Corporation today announced that data from a large, prospective, randomized, controlled Phase 2b clinical trial of Ophthotech's Fovista anti-PDGF therapy (1.5 mg) in patients with neovascular age-related macular degeneration (wet AMD) will be presented during Retina Subspecialty Day at the American Academy of Ophthalmology Annual Meeting (AAO) on Sat., Nov. 10, 2012 at 9:15 a.m.

25 Oct 2012

VEGF produced by NPCs plays a strong role in influencing microglial behavior

The brain's key "breeder" cells, it turns out, do more than that. They secrete substances that boost the numbers and strength of critical brain-based immune cells believed to play a vital role in brain health. This finding adds a new dimension to our understanding of how resident stem cells and stem cell transplants may improve brain function.

22 Oct 2012

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

Pfizer Inc. announced today that a Phase 3 study of INLYTA (axitinib) did not meet its primary endpoint of demonstrating statistically significantly longer progression-free survival, versus sorafenib, in treatment-naïve patients with advanced renal cell carcinoma.

18 Oct 2012

Downregulated protein could be revascularization target in critical limb ischemia

Levels of calcium-sensor protein, S100A1, are downregulated in patients with critical limb ischemia, say researchers who believe the protein could be a potential therapeutic target to promote revascularization.

12 Oct 2012

Ranibizumab improves driving prospects for AMD patients

Treatment with ranibizumab can preserve and even improve the perceived driving ability of patients with age-related macular degeneration, show the results of two randomized trials.

10 Oct 2012

Pieris achieves milestone in Anticalin discovery and development collaboration with Daiichi Sankyo

Pieris AG announced today the achievement of the first financial milestone in its discovery and development collaboration with Daiichi Sankyo Company Limited.

9 Oct 2012

Assisted reproduction technology may increase risk of MS activity among women

Researchers in Argentina report that women with multiple sclerosis (MS) who undergo assisted reproduction technology (ART) infertility treatment are at risk for increased disease activity.

4 Oct 2012

New insights on mechanisms involved in regeneration of insulin-producing cells

Researchers at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute have found that a blood vessel-building gene boosts the ability of human bone marrow stem cells to sustain pancreatic recovery in a laboratory mouse model of insulin-dependent diabetes.

3 Oct 2012

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Exelixis, Inc. today announced interim data from 51 patients with metastatic castration-resistant prostate cancer (CRPC) and bone metastases receiving a 40 mg daily dose of cabozantinib in an ongoing non-randomized expansion (NRE) cohort of a phase 2 randomized discontinuation trial.

1 Oct 2012

Exelix reports preliminary data from cabozantinib phase 1 study on solid tumors

Exelixis, Inc. today reported preliminary data from an ongoing phase 1 dose escalation study of cabozantinib in Japan.

1 Oct 2012

New trial results on pazopanib and temsirolimus have important implications for patients with RCC

New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

1 Oct 2012

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Eli Lilly and Company today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC).

1 Oct 2012

Synta announces results from ganetespib Phase 2b trial on NSCLC

Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).

29 Sep 2012

VEGF News and Research

Further Reading

Combination of perifosine and temsirolimus shows promise against malignant glioma

Bevacizumab ruled out for stage III colorectal cancer

Positive results from Genentech Avastin plus temozolomide Phase III study on glioblastoma

Study: Regular exercise before, during pregnancy could have beneficial effects for women

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Adding angiogenesis inhibitor to anti-HER2 drugs extends survival in mice with breast cancer

Targeted deletion of major VEGF gene in mice induces vision loss

Ophthotech announces data from Fovista Phase 2b trial on wet AMD

VEGF produced by NPCs plays a strong role in influencing microglial behavior

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

Downregulated protein could be revascularization target in critical limb ischemia

Ranibizumab improves driving prospects for AMD patients

Pieris achieves milestone in Anticalin discovery and development collaboration with Daiichi Sankyo

Assisted reproduction technology may increase risk of MS activity among women

New insights on mechanisms involved in regeneration of insulin-producing cells

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Exelix reports preliminary data from cabozantinib phase 1 study on solid tumors

New trial results on pazopanib and temsirolimus have important implications for patients with RCC

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Synta announces results from ganetespib Phase 2b trial on NSCLC

Latest eBooks

Industry focus eBook - The Digital Laboratory (4th edition)

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (3rd Edition)

BFEB: Advances in microplate-based assays and analysis

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation